Muscle-invasive Bladder Cancer Therapeutics Market Size, Share, and Growth Forecast for 2025 - 2032

Muscle-invasive Bladder Cancer Therapeutics Market by Cancer Grade (Low-grade Bladder Cancer, High-grade Bladder Cancer), by Drug Type (Immunotherapy, Chemotherapy, Targeted Therapy, by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies), and Regional Analysis

ID: PMRREP32147

Format: PPT*, PDF, EXCEL

Last Updated: 7 Aug 2025

Industry: Healthcare

Number of Pages: 321

Persistence Market Research Report, Market Growth and Regional Outlook

Table of Content

  1. Executive Summary
    1. Global Muscle-invasive Bladder Cancer Therapeutics Market Snapshot 2025 and 2032
    2. Market Opportunity Assessment, 2025-2032, US$ Mn
    3. Key Market Trends
    4. Industry Developments and Key Market Events
    5. Demand Side and Supply Side Analysis
    6. PMR Analysis and Recommendations
  2. Market Overview
    1. Market Scope and Definitions
    2. Value Chain Analysis
    3. Macro-Economic Factors
      1. Global GDP Outlook
      2. Global Construction Industry Overview
      3. Global Mining Industry Overview
    4. Forecast Factors – Relevance and Impact
    5. COVID-19 Impact Assessment
    6. PESTLE Analysis
    7. Porter's Five Forces Analysis
    8. Geopolitical Tensions: Market Impact
    9. Regulatory and Technology Landscape
  3. Market Dynamics
    1. Drivers
    2. Restraints
    3. Opportunities
    4. Trends
  4. Price Trend Analysis, 2019 – 2032
    1. Region-wise Price Analysis
    2. Price by Segments
    3. Price Impact Factors
  5. Global Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
    1. Key Highlights
    2. Global Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Cancer Grade
      1. Introduction/Key Findings
      2. Historical Market Size (US$ Mn) Analysis by Cancer Grade, 2019-2024
      3. Current Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
        1. Low-grade Bladder Cancer
        2. High-grade Bladder Cancer
      4. Market Attractiveness Analysis: Cancer Grade
    3. Global Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Drug Type
      1. Introduction/Key Findings
      2. Historical Market Size (US$ Mn) Analysis by Drug Type, 2019-2024
      3. Current Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
        1. Immunotherapy
          1. Bacillus Calmette-Guerin
          2. Avelumab
          3. Nivolumab
          4. Pembrolizumab
          5. Others
        2. Chemotherapy
          1. Mitomycin C
          2. Docetaxel
          3. Paclitaxel
          4. Cisplatin
          5. Others
        3. Targeted Therapy
          1. Erdafitinib
          2. Enfortumab Vedotin-ejfv
          3. Sacituzumab Govitecan
          4. Others
      4. Market Attractiveness Analysis: Drug Type
    4. Global Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Distribution Channel
      1. Introduction/Key Findings
      2. Historical Market Size (US$ Mn) Analysis by Distribution Channel, 2019-2024
      3. Current Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
        1. Hospitals Pharmacies
        2. Retail Pharmacies
        3. Specialty Pharmacies
        4. Online Pharmacies
      4. Market Attractiveness Analysis: Distribution Channel
  6. Global Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Region
    1. Key Highlights
    2. Historical Market Size (US$ Mn) Analysis by Region, 2019-2024
    3. Current Market Size (US$ Mn) Forecast, by Region, 2025-2032
      1. North America
      2. Europe
      3. East Asia
      4. South Asia & Oceania
      5. Latin America
      6. Middle East & Africa
    4. Market Attractiveness Analysis: Region
  7. North America Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
    1. Key Highlights
    2. Pricing Analysis
    3. North America Market Size (US$ Mn) Forecast, by Country, 2025-2032
      1. U.S.
      2. Canada
    4. North America Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
      1. Low-grade Bladder Cancer
      2. High-grade Bladder Cancer
    5. North America Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
      1. Immunotherapy
        1. Bacillus Calmette-Guerin
        2. Avelumab
        3. Nivolumab
        4. Pembrolizumab
        5. Others
      2. Chemotherapy
        1. Mitomycin C
        2. Docetaxel
        3. Paclitaxel
        4. Cisplatin
        5. Others
      3. Targeted Therapy
        1. Erdafitinib
        2. Enfortumab Vedotin-ejfv
        3. Sacituzumab Govitecan
        4. Others
    6. North America Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
      1. Hospitals Pharmacies
      2. Retail Pharmacies
      3. Specialty Pharmacies
      4. Online Pharmacies
  8. Europe Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
    1. Key Highlights
    2. Pricing Analysis
    3. Europe Market Size (US$ Mn) Forecast, by Country, 2025-2032
      1. Germany
      2. Italy
      3. France
      4. U.K.
      5. Spain
      6. Russia
      7. Rest of Europe
    4. Europe Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
      1. Low-grade Bladder Cancer
      2. High-grade Bladder Cancer
    5. Europe Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
      1. Immunotherapy
        1. Bacillus Calmette-Guerin
        2. Avelumab
        3. Nivolumab
        4. Pembrolizumab
        5. Others
      2. Chemotherapy
        1. Mitomycin C
        2. Docetaxel
        3. Paclitaxel
        4. Cisplatin
        5. Others
      3. Targeted Therapy
        1. Erdafitinib
        2. Enfortumab Vedotin-ejfv
        3. Sacituzumab Govitecan
        4. Others
    6. Europe Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
      1. Hospitals Pharmacies
      2. Retail Pharmacies
      3. Specialty Pharmacies
      4. Online Pharmacies
  9. East Asia Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
    1. Key Highlights
    2. Pricing Analysis
    3. East Asia Market Size (US$ Mn) Forecast, by Country, 2025-2032
      1. China
      2. Japan
      3. South Korea
    4. East Asia Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
      1. Low-grade Bladder Cancer
      2. High-grade Bladder Cancer
    5. East Asia Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
      1. Immunotherapy
        1. Bacillus Calmette-Guerin
        2. Avelumab
        3. Nivolumab
        4. Pembrolizumab
        5. Others
      2. Chemotherapy
        1. Mitomycin C
        2. Docetaxel
        3. Paclitaxel
        4. Cisplatin
        5. Others
      3. Targeted Therapy
        1. Erdafitinib
        2. Enfortumab Vedotin-ejfv
        3. Sacituzumab Govitecan
        4. Others
    6. East Asia Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
      1. Hospitals Pharmacies
      2. Retail Pharmacies
      3. Specialty Pharmacies
      4. Online Pharmacies
  10. South Asia & Oceania Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
    1. Key Highlights
    2. Pricing Analysis
    3. South Asia & Oceania Market Size (US$ Mn) Forecast, by Country, 2025-2032
      1. India
      2. Southeast Asia
      3. ANZ
      4. Rest of SAO
    4. South Asia & Oceania Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
      1. Low-grade Bladder Cancer
      2. High-grade Bladder Cancer
    5. South Asia & Oceania Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
      1. Immunotherapy
        1. Bacillus Calmette-Guerin
        2. Avelumab
        3. Nivolumab
        4. Pembrolizumab
        5. Others
      2. Chemotherapy
        1. Mitomycin C
        2. Docetaxel
        3. Paclitaxel
        4. Cisplatin
        5. Others
      3. Targeted Therapy
        1. Erdafitinib
        2. Enfortumab Vedotin-ejfv
        3. Sacituzumab Govitecan
        4. Others
    6. South Asia & Oceania Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
      1. Hospitals Pharmacies
      2. Retail Pharmacies
      3. Specialty Pharmacies
      4. Online Pharmacies
  11. Latin America Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
    1. Key Highlights
    2. Pricing Analysis
    3. Latin America Market Size (US$ Mn) Forecast, by Country, 2025-2032
      1. Brazil
      2. Mexico
      3. Rest of LATAM
    4. Latin America Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
      1. Low-grade Bladder Cancer
      2. High-grade Bladder Cancer
    5. Latin America Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
      1. Immunotherapy
        1. Bacillus Calmette-Guerin
        2. Avelumab
        3. Nivolumab
        4. Pembrolizumab
        5. Others
      2. Chemotherapy
        1. Mitomycin C
        2. Docetaxel
        3. Paclitaxel
        4. Cisplatin
        5. Others
      3. Targeted Therapy
        1. Erdafitinib
        2. Enfortumab Vedotin-ejfv
        3. Sacituzumab Govitecan
        4. Others
    6. Latin America Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
      1. Hospitals Pharmacies
      2. Retail Pharmacies
      3. Specialty Pharmacies
      4. Online Pharmacies
  12. Middle East & Africa Muscle-invasive Bladder Cancer Therapeutics Market Outlook: Historical (2019 – 2024) and Forecast (2025 – 2032)
    1. Key Highlights
    2. Pricing Analysis
    3. Middle East & Africa Market Size (US$ Mn) Forecast, by Country, 2025-2032
      1. GCC Countries
      2. South Africa
      3. Northern Africa
      4. Rest of MEA
    4. Middle East & Africa Market Size (US$ Mn) Forecast, by Cancer Grade, 2025-2032
      1. Low-grade Bladder Cancer
      2. High-grade Bladder Cancer
    5. Middle East & Africa Market Size (US$ Mn) Forecast, by Drug Type, 2025-2032
      1. Immunotherapy
        1. Bacillus Calmette-Guerin
        2. Avelumab
        3. Nivolumab
        4. Pembrolizumab
        5. Others
      2. Chemotherapy
        1. Mitomycin C
        2. Docetaxel
        3. Paclitaxel
        4. Cisplatin
        5. Others
      3. Targeted Therapy
        1. Erdafitinib
        2. Enfortumab Vedotin-ejfv
        3. Sacituzumab Govitecan
        4. Others
    6. Middle East & Africa Market Size (US$ Mn) Forecast, by Distribution Channel, 2025-2032
      1. Hospitals Pharmacies
      2. Retail Pharmacies
      3. Specialty Pharmacies
      4. Online Pharmacies
  13. Competition Landscape
    1. Market Share Analysis, 2024
    2. Market Structure
      1. Competition Intensity Mapping
      2. Competition Dashboard
    3. Company Profiles
      1. Pfizer Inc.
        1. Company Overview
        2. Product Portfolio/Offerings
        3. Key Financials
        4. SWOT Analysis
        5. Company Strategy and Key Developments
      2. Merck KGaA
      3. AstraZeneca PLC
      4. Roche Holding AG (Genentech)
      5. Astella
      6. J&J (Janssen Biotech)
      7. Cipla Inc.
      8. Amneal Pharma
      9. Bristol Myers Squibb Co.
      10. Dr. Reddy’s Laboratories, Inc.
      11. Gilead Sciences Inc.
      12. Endo Pharma
      13. UroGen Pharma, Inc.
      14. Teva Pharmaceuticals (Actavis)
      15. Hikma Pharmaceuticals
  14. Appendix
    1. Research Methodology
    2. Research Assumptions
    3. Acronyms and Abbreviations

Thank you for taking time to visit our website, click like if you found the information on this page useful?

This site uses cookies, including third-party cookies, that help us to provide and improve our services.
Google translate